Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Gavin GiovannoniGiancarlo ComiKottil RammohanPeter RieckmannFernando DangondBirgit KellerDominic JackPatrick VermerschPublished in: Advances in therapy (2021)
ClinicalTrials.gov NCT00213135 (CLARITY); NCT00641537 (CLARITY Extension).